A study on the aspects of pharmacoepidemiology and pharmacohaemovigilance of ferrous ascorbate, ferrous fumarate, ferrous sulphate and ferric ammonium citrate, among the rural anaemic women, in the Indian spectrum


  • Moumita Hazra Department of Pharmacology, Gouri Devi Institute of Medical Sciences and Hospital, Durgapur, West Bengal




Pharmacoepidemiology, Pharmacohaemovigilance, Ferrous ascorbate, Ferrous fumarate, Ferrous sulphate, Ferric ammonium citrate


Background: Anaemia is a global health concern, associated with increased maternal and perinatal mortality, preterm delivery, low birth weight, extreme fatigue and impaired immune system; and controlled by oral haematinics; with a rise in haemoglobin concentration. The objective was to examine the various aspects of pharmacoepidemiology and pharmacohaemovigilance of oral haematinics, among the anaemic women population, in rural India.

Methods: This was a multi-centre, retrospective, observational and analytical study of the hospital medical records of 250 anaemic patients, who were allocated into group A of 125 patients within 15-21 years and group B of 125 patients within 22-35 years. The patients were prescribed oral haematinics, containing 60 mg of elemental iron, thrice daily, with meals. The various aspects of pharmacoepidemiology and pharmacohaemovigilance of ferrous ascorbate, ferrous sulphate, ferrous fumarate and ferric ammonium citrate, including patients’ demographic characteristics, anaemic symptoms assessment, prescription patterns, and safety assessment, on 1st, 2nd, 3rd months and follow-up visits, were recorded and thoroughly analysed..

Results: In groups A and B, the demographic characteristics of the patients were comparable; ferrous ascorbate was the most commonly prescribed oral haematinic, followed by ferrous sulphate, ferrous fumarate and ferric ammonium citrate, which controlled mild to moderate iron deficiency anaemia, with a gradual significant rise in haemoglobin concentration, in the successive 3 months; and adverse effects were observed to be statistically non-significant in either group.

Conclusions: The different aspects of pharmacoepidemiology and pharmacohaemovigilance in the study established that the oral haematinics were reasonably beneficial and safe among the anaemic women population, in rural India.


Kaushansky K, Kipps TJ. Haematopoietic agents: growth factors, minerals, and vitamins. In: Brunton LL, Chabner BA, Knollmann BC, ed. Goodman and Gilman’s The pharmacological basis of therapeutics. 12th ed. USA: McGraw Hill; 2011:1076-85.

INACG. INACG Symposium. Washington DC: ILSI Research Foundation; 2000.

Wu TW, Tsai FP. Comparison of the therapeutic effects and side effects of oral iron supplements in iron deficiency anaemia. Drug Res. 2016;66(05):257-61.

UNICEF/UNU/WHO. Iron deficiency anemia: assessment, prevention, and control. Geneva, Switzerland: WHO; 2001.

Hercberg S, Preziosi P, Briançon S, Galan P, Triol I, Malvy D, et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.Vi.Max study – design, methods, and participant characteristics. Control Clin Trials. 1998;19:336-51.

Iron and folate supplementation. Integrated management of pregnancy and childbirth. In: Standards for maternal and neonatal care. Geneva: Department of Making Pregnancy Safer, World Health Organization; 2006.

Adamson JW. Iron deficiency and other hypoproliferative anaemias. In: Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 18th ed. Delhi, India: Mc Graw Hill; 2011: 586-593.

Cook K. Haematologic disorders: Anaemias. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 10th ed. USA: McGraw Hill; 2011: 1023-1047.

Masters SB. Agents used in anaemia; haematopoietic growth factors. In: Katzung BG, Masters SB, Trevor AJ, eds. Basic Clin Pharmacol. 12th ed. McGraw Hill Lange; 2013: 581-659.

United Nations Children’s Fund/World Health Organisation. Prevention and control of iron deficiency anaemia in women and children. Geneva, Switzerland: UNICEF/WHO; 1999.

Lanzkowsky P. Iron-deficiency anaemia. In: Manual of Paediatric Haematology and Oncology. 5th ed. Netherlands, UK, USA, Singapore, Australia, Japan: Elsevier; 2011. 38-57.

Bennett PN, Brown MJ. Cellular disorders and anaemias. In: Horne T, ed. Clinical Pharmacology. 9th ed. UK, USA, Australia, Canada: Churchill Livingstone; 2003: 587-593.

Erber WN. Red blood cell disorders. In: Bennett PN, Brown MJ, Sharma P, eds. Clinical Pharmacology. 11th ed. UK, USA, Australia, Canada: Churchill Livingstone; 2012: 496-500.

Lee D, Majumdar SR, Lipton HL, Soumerai SB, Hennessy S, Davis RL, et al. Special applications of pharmacoepidemiology. In: Strom BL, Kimmel SE, eds. Textbook of Pharmacoepidemiology. West Sussex: John Wiley and Sons Ltd; 2006: 397-442.

ACC/SCN. Fourth report on the World Nutrition Situation. Geneva: Administrative Committee on Coordination: Subcommittee on Nutrition in collaboration (ACC/SCN) with IFPRI; 2000.

Gibson HM. Plasma volume and glomerular filtration rate in pregnancy and their relation to differences in fetal growth. J Obstet Gynaecol Br Commonw. 1973;80(12):1067-74.

Ross JS, Thomas EL. Iron deficiency anemia and maternal mortality. Washington, DC: Academy of Educational Development; 1996.

Sarin A. Severe anaemia of pregnancy, recent experience. Intl J Gynaecol Obstet. 1995;2:43-9.

Murphy J, O'Riordan J, Newcombe R, Coles E, Pearson J. Relation of haemoglobin levels in first and second trimesters to outcome of pregnancy. Lancet. 1986;1:992-5.

Lieberman E, Ryan K, Monson R, Schoenbaum S. Risk factors accounting for racial differences in the rate of premature birth. N Engl J Med. 1987;317:743-8.

Yip R. Significance of an abnormally low or high haemoglobin concentration during pregnancy: special consideration of iron nutrition. Am J Clin Nutr. 2000;72:272-9.

Whitfield CR. Blood disorders in pregnancy. In: Whitfield CR, ed. Dewhurst’s textbook of Obstetrics and Gynaecology for postgraduates. 5th ed. Oxford: Blackwell Science; 1995: 228-236.

WHO/UNICEF/UNU. Indicators of assessing iron deficiency and strategies for its prevention. Geneva: World Health Organization; 1996.

Breymann C. Iron deficiency anaemia in pregnancy. Semin Hematol. 2015;52(4):339-47.

Rao B, Vijayasarathy C, Prabhavathi T. Iron absorption from habitual diets of Indians studied by extrinsic tag techniques. Indian J Med Res. 1983;77:648-57.

Agarwal MB, Rathi SA. An open-label, randomized, comparative clinical study to assess the efficacy and tolerability of ferrous ascorbate versus carbonyl iron in the treatment of iron deficiency anaemia. Int J Gynecol and Obstet. India 2005;8:23-30.

Sarkate P, Patil A, Parulaker S, Rege NN, Samani BD, Lokhande J, et al. A randomised double blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy. JAMA. 2007;195:278-89.

Singhal SR, Kadian V, Singh S, Ghalaut VS. Comparison of various oral iron salts in the treatment of iron deficiency anemia in pregnancy. Indian J Obstet Gynecol Res. 2015;2(3):155-8.

Mistry N, Joshi H, Sood S, Shah S, Malhotra S. Efficacy and tolerability of ferrous sulphate vs iron peptone+ferrous ascorbate in pregnancy: an observational study. Natl J Integr Res Med. 2018;9(5):16-9.




How to Cite

Hazra, M. (2019). A study on the aspects of pharmacoepidemiology and pharmacohaemovigilance of ferrous ascorbate, ferrous fumarate, ferrous sulphate and ferric ammonium citrate, among the rural anaemic women, in the Indian spectrum. International Journal of Basic & Clinical Pharmacology, 8(12), 2751–2758. https://doi.org/10.18203/2319-2003.ijbcp20195291



Original Research Articles